{"nctId":"NCT00389064","briefTitle":"Efficacy and Safety Study of Seroquel SR in the Treatment of Generalised Anxiety Disorder","startDateStruct":{"date":"2006-09"},"conditions":["Anxiety Disorders"],"count":450,"armGroups":[{"label":"Quetapine XR","type":"EXPERIMENTAL","interventionNames":["Drug: Quetiapine XR"]},{"label":"Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Quetiapine XR","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female patients, 66 years or older, with a documented clinical diagnosis of Generalised Anxiety Disorder (GAD).\n* Absence of current episode of major depression.\n\nExclusion Criteria:\n\n* The presence of dementia or other mental disorder than GAD.\n* Serious suicidal risk, uncontrolled hypertension, substance or alcohol abuse.\n* A current diagnosis of cancer or current or past diagnosis of stroke.","healthyVolunteers":false,"sex":"ALL","minimumAge":"66 Years","stdAges":["OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in the Hamilton Rating Scale for Anxiety (HAM-A) Total Score","description":"HAM-A total score ( 0-56 units), 0 is the best, Change : score at week 9 minus score at randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-14.97","spread":"7.4"},{"groupId":"OG001","value":"-7.21","spread":"7.8"}]}]}]},{"type":"SECONDARY","title":"Change in Health-related Quality of Life as Measured by Quality of Life Enjoyment and Satisfaction Questionnaire (Q-LES-Q) Percent Maximum Total Score","description":"Q-LES-Q total score is the sum of the first 14 items of Q-LES-Q, and this total score is converted to a % maximum total score by : (Q-LES-Q total score -14) /56 x 100%, Larger values indicate a higher perceived quality of life enjoyment and satisfaction.\n\nChange : percentage at week 9 minus percentage at randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14.82","spread":"12.40"},{"groupId":"OG001","value":"4.94","spread":"11.60"}]}]}]},{"type":"SECONDARY","title":"Change in the Clinical Global Impression - Severity of Illness (CGI-S) Score","description":"CGI-S score is accessed on a seven-graded scale ranging from most extremely ill/ very much worse (7) to normal/very much improved (1) , 1 is best Change : score at week 9 minus score at randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.76","spread":"1.10"},{"groupId":"OG001","value":"-0.59","spread":"1.00"}]}]}]},{"type":"SECONDARY","title":"Change in Psychic Anxiety Factor as Measured by HAM-A Psychic Cluster Score","description":"HAM-A psychic cluster score ( 0-28), 0 is the best Change : score at week 9 minus score at randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-8.88","spread":"4.20"},{"groupId":"OG001","value":"-3.81","spread":"4.60"}]}]}]},{"type":"SECONDARY","title":"Change in Somatic Symptoms as Measured by HAM-A Somatic Cluster Score","description":"HAM-A somatic cluster score (0-28), 0 is the best Change : score at week 9 minus score at randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.05","spread":"4.00"},{"groupId":"OG001","value":"-3.37","spread":"3.90"}]}]}]},{"type":"SECONDARY","title":"Hamilton Rating Scale for Anxiety (HAM-A) Response.","description":"HAM-A response, defined as 50% or greater reduction from randomization in HAM-A total score.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"152","spread":null},{"groupId":"OG001","value":"54","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Reaching Hamilton Rating Scale for Anxiety (HAM-A) Remission","description":"HAM-A remission, defined as HAM-A total score less or equal to 7. An indicator of HAM-A remission is calculated as:\n\n* If HAM-A total scoreâ‰¤7, THEN indicator=1\n* If HAM-A total score \\>7, THEN indicator=0","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"89","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Montgomery-Asberg Depression Rating Scale (MADRS)","description":"MADRS total score (0-60), 0 is best Change : score at week 9 minus score at randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-6.94","spread":"4.70"},{"groupId":"OG001","value":"-2.22","spread":"4.70"}]}]}]},{"type":"SECONDARY","title":"Change in the Visual Analogue Scale (VAS) Measuring Pain","description":"Visual Analogue Scale (VAS) measuring pain (0-100 mm), 0 is best Change : scale at week 9 minus scale at randomization","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-17.95","spread":"21.80"},{"groupId":"OG001","value":"-6.18","spread":"19.80"}]}]}]},{"type":"SECONDARY","title":"Safety and Well Tolerated as Measured in Adverse Event","description":"Number of patients have at least one adverse event","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"145.00","spread":null},{"groupId":"OG001","value":"114.00","spread":null}]}]}]},{"type":"SECONDARY","title":"Safety and Well Tolerated as Measured by Extra Pyramidal Symptoms (EPS)","description":"Number of patients have adverse events associated with EPS","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12.00","spread":null},{"groupId":"OG001","value":"5.00","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":1,"n":223},"commonTop":["Somnolence","Headache","Dry Mouth","Dizziness","Nausea"]}}}